Back

Thiogenesis updates shareholders on TTI-0102 pediatric disease program

Verifying
  • Thiogenesis Therapeutics announced shareholder approvals and updates on TTI-0102.
  • TTI-0102 targets nephropathic cystinosis and Leigh syndrome.
  • Thiogenesis plans to begin clinical studies of its lead drug candidate.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.